October 29th 2021
Bradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.
August 19th 2021
Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.
July 28th 2021
Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.
June 1st 2021
Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.
Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.
May 25th 2021
Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.
Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.
May 19th 2021
Bradley J. Monk, MD, FACS, FACOG, highlights current guidelines for utilizing maintenance PARP inhibitors in the treatment of patients with ovarian cancer.
May 18th 2021
Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.
Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.
April 29th 2021
Bradley J. Monk, MD, FACS, FACOG, discusses the clinical implications of the phase 3 PRIMA trial in newly diagnosed advanced ovarian cancer.
January 4th 2021